Compare Sanofi SA (SNY) vs Pacer Data & Infra Real Estate ETF (SRVR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Pacer Data & Infra Real Estate ETF — how do they compare? Sanofi SA trades at $42.7 (market cap $104.06B), while Pacer Data & Infra Real Estate ETF trades at $30.7. The key difference: Sanofi SA pays a 5.61% dividend while Pacer Data & Infra Real Estate ETF pays none, and Pacer Data & Infra Real Estate ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| SNY | SRVR | |
|---|---|---|
Market Cap | $104.06B | — |
Sector | Health | Sector/Thematic |
52-Week High | $52.34 | $35.74 |
52-Week Low | $41.33 | $28.54 |
Enterprise Value | $124.09B | — |
Dividend Yield | 5.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Pacer Data & Infra Real Estate ETF
Pacer Data & Infra Real Estate ETF seeks exposure to real estate companies that own digital infrastructure assets. Its holdings may include data centers, cell towers, fiber networks, and other connectivity-related real estate.
Read more on SRVR →
